141 related articles for article (PubMed ID: 3480271)
21. Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2 fragments of the OC125 antibody.
Reinsberg J; Nocke W
Eur J Clin Chem Clin Biochem; 1993 May; 31(5):323-7. PubMed ID: 8357942
[TBL] [Abstract][Full Text] [Related]
22. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells.
Matsuoka Y; Nakashima T; Endo K; Yoshida T; Kunimatsu M; Sakahara H; Koizumi M; Nakagawa T; Yamaguchi N; Torizuka K
Cancer Res; 1987 Dec; 47(23):6335-40. PubMed ID: 3315184
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of a radiolabeled monoclonal antibody on human ovarian cancer xenograft in nude mice.
Manetta A; Satyaswaroop PG; Hamilton T; Ozols R; Mortel R
Gynecol Oncol; 1989 Mar; 32(3):368-70. PubMed ID: 2920960
[TBL] [Abstract][Full Text] [Related]
24. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.
Kabawat SE; Bast RC; Bhan AK; Welch WR; Knapp RC; Colvin RB
Int J Gynecol Pathol; 1983; 2(3):275-85. PubMed ID: 6196309
[TBL] [Abstract][Full Text] [Related]
25. Confirmation of a false-positive result in CA 125 immunoradiometric assay caused by human anti-idiotypic immunoglobulin.
Klug TL; Green PJ; Zurawski VR; Davis HM
Clin Chem; 1988 Jun; 34(6):1071-6. PubMed ID: 2454168
[TBL] [Abstract][Full Text] [Related]
26. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
27. Clinical immunoscintigraphy of ovarian carcinoma using iodine-131-labeled 145-9 monoclonal antibody.
Chung JK; Kang SB; Lee HP; Lee MC; Koh CS; Sakahara H; Endo K
J Nucl Med; 1993 Oct; 34(10):1651-5. PubMed ID: 8410277
[TBL] [Abstract][Full Text] [Related]
28. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL; Hayes DF; Kufe DW
Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
Muto MG; Finkler NJ; Kassis AI; Howes AE; Anderson LL; Lau CC; Zurawski VR; Weadock K; Tumeh SS; Lavin P
Gynecol Oncol; 1992 Jun; 45(3):265-72. PubMed ID: 1612502
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: correlation with histopathological features, prognostic variables and patient outcome.
Friedlander M; Leary J; Russell P
Pathology; 1988 Jan; 20(1):38-44. PubMed ID: 3163797
[TBL] [Abstract][Full Text] [Related]
32. [CA125 and radioimmunoimaging in monitoring of epithelial ovarian carcinoma].
Yu Q; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 1991 Jul; 26(4):235-8, 252. PubMed ID: 1914661
[TBL] [Abstract][Full Text] [Related]
33. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Molthoff CF; Buist MR; Kenemans P; Pinedo HM; Boven E
J Nucl Med; 1992 Nov; 33(11):2000-5. PubMed ID: 1432162
[TBL] [Abstract][Full Text] [Related]
34. OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment.
Maughan TS; Haylock B; Hayward M; Facey P; Evans WD; Shelley MD; Fish RG; Adams M
Clin Oncol (R Coll Radiol); 1990 Jul; 2(4):199-205. PubMed ID: 2261415
[TBL] [Abstract][Full Text] [Related]
35. Immunoscintigraphy of recurrences of gynecologic carcinomas.
Chatal JF; Fumoleau P; Saccavini JC; Thedrez P; Curtet C; Bianco-Arco A; Chetanneau A; Peltier P; Kremer M; Guillard Y
J Nucl Med; 1987 Dec; 28(12):1807-19. PubMed ID: 3500284
[TBL] [Abstract][Full Text] [Related]
36. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Sekine H; Hayes DF; Ohno T; Keefe KA; Schaetzl E; Bast RC; Knapp R; Kufe DW
J Clin Oncol; 1985 Oct; 3(10):1355-63. PubMed ID: 2413181
[TBL] [Abstract][Full Text] [Related]
37. False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.
Reinsberg J; Wagner U; Krebs D
Arch Gynecol Obstet; 1994; 255(1):9-18. PubMed ID: 8042882
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
39. Idiotypic cascades after MAb OC125 application.
Reinsberg J
Hybridoma; 1993 Oct; 12(5):577-82. PubMed ID: 8300133
[No Abstract] [Full Text] [Related]
40. [Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian cancer cell lines].
Murakami F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Feb; 48(2):125-32. PubMed ID: 8718548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
